Forskargruppen som utvecklat prototypen för ColoNode består av Lina Olsson, Sten Hammarström, Gudrun Lindmark, Marie-Louise Hammarström och Anne Israelsson.
Hiloprobe receives a lot of positive interest and new investments.

6 million SEK investment for Hiloprobe

Hiloprobe with new investment partners secures funds to perform further verification activities.

Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field.

The third most common cancer

Colorectal cancer is the third most common cancer today. Each year 1.4 million individuals are being diagnosed worldwide. With mortality rates surpassing 50 percent, improved diagnostics, prognosing and better treatments are essential in order to improve survival and quality of life for those affected by the disease.

Read more in Swedish.